{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:58:40Z","timestamp":1778047120681,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00198-025-07540-y","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:59:37Z","timestamp":1748581177000},"page":"1257-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Characteristics and treatment options of 272,152 geriatric patients with very high and high fracture risk"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1583-1577","authenticated-orcid":false,"given":"Michaela","family":"Rippl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Schluessel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Schmidmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Tausendfreund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"T\u00fcmena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Drey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"6","key":"7540_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","volume":"94","author":"Consensus development conference","year":"1993","unstructured":"Consensus development conference (1993) diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94(6):646\u2013650","journal-title":"Am J Med"},{"issue":"1","key":"7540_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16(1):82","journal-title":"Arch Osteoporos"},{"issue":"1","key":"7540_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3\u201344","journal-title":"Osteoporos Int"},{"issue":"1","key":"7540_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","volume":"11","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Od\u00e9n A, McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11(1):25","journal-title":"Arch Osteoporos"},{"issue":"1","key":"7540_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E, Bruy\u00e8re O, Veronese N, Lorentzon M et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31(1):1\u201312","journal-title":"Osteoporos Int"},{"issue":"16","key":"7540_CR6","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543","journal-title":"N Engl J Med"},{"issue":"15","key":"7540_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427","journal-title":"N Engl J Med"},{"issue":"10117","key":"7540_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391(10117):230\u2013240","journal-title":"Lancet"},{"issue":"10","key":"7540_CR9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00198-020-05463-4","volume":"31","author":"JJ Body","year":"2020","unstructured":"Body JJ, Marin F, Kendler DL, Zerbini CAF, L\u00f3pez-Romero P, M\u00f6ricke R et al (2020) Efficacy of teriparatide compared with risedronate on FRAX(\u00ae)-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporos Int 31(10):1935\u20131942","journal-title":"Osteoporos Int"},{"key":"7540_CR10","doi-asserted-by":"publisher","unstructured":"Thomasius F, Kurth A, Baum E, Drey M, Maus U, Schmidmaier R (2025) Clinical practice guideline: the diagnosis and treatment of osteoporosis. Dtsch Arztebl Int 122(1):12\u201318. https:\/\/doi.org\/10.3238\/arztebl.m2024.0222","DOI":"10.3238\/arztebl.m2024.0222"},{"key":"7540_CR11","unstructured":"(GiB-DAT) GiB-D. Geriatrie in Bayern Datenbank 2024. Available from: https:\/\/www.gibdat.de\/ueber\/#. Accessed 16 Jul 2024"},{"issue":"02","key":"7540_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/a-2034-6086","volume":"32","author":"R Schmidmaier","year":"2023","unstructured":"Schmidmaier R, Hadji P, Kern P, Drey M, Jakob F, Thomasius F (2023) Recommendations for the pharmacological treatment of osteoporosis\u2013update 2023 of the german osteoporosis guideline. Osteologie 32(02):115\u2013122","journal-title":"Osteologie"},{"issue":"1","key":"7540_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11657-022-01175-w","volume":"17","author":"HP Dimai","year":"2022","unstructured":"Dimai HP, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L et al (2022) Osteoporosis treatment in Austria-assessment of FRAX-based intervention thresholds for high and very high fracture risk. Arch Osteoporos 17(1):141","journal-title":"Arch Osteoporos"},{"key":"7540_CR14","unstructured":"Looker AC, Borrud LG, Dawson-Hughes B, Shepherd JA, Wright NC (2012) Osteoporosis or low bone mass at the femur neck or lumbar spine in older adults: United States, 2005-2008.NCHS Data Brief (93):1\u20138"},{"key":"7540_CR15","doi-asserted-by":"publisher","unstructured":"Rippl M, Grupp P, Martini S, M\u00fcller K, Tausendfreund O, Schmidmaier R, Drey M (2025) Characteristics of patients with very high fracture risk in a community-dwelling geriatric cohort. Bone 192:117366. https:\/\/doi.org\/10.1016\/j.bone.2024.117366","DOI":"10.1016\/j.bone.2024.117366"},{"issue":"1","key":"7540_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11657-024-01380-9","volume":"19","author":"P Hadji","year":"2024","unstructured":"Hadji P, Esterberg E, Oberm\u00fcller D, Bartsch R (2024) Bone evaluation study-2: update on the epidemiology of osteoporosis in Germany. Arch Osteoporos 19(1):26","journal-title":"Arch Osteoporos"},{"issue":"10","key":"7540_CR17","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00198-021-05942-2","volume":"32","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L et al (2021) An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: a report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int 32(10):1951\u20131960","journal-title":"Osteoporos Int"},{"key":"7540_CR18","doi-asserted-by":"publisher","unstructured":"Rinonapoli G, Ruggiero C, Meccariello L, Bisaccia M, Ceccarini P, Caraffa A (2021) Osteoporosis in men: a review of an underestimated bone condition. Int J Mol Sci 22(4):2105. https:\/\/doi.org\/10.3390\/ijms22042105","DOI":"10.3390\/ijms22042105"},{"issue":"Suppl 1","key":"7540_CR19","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.injury.2020.02.009","volume":"51","author":"A Delgado","year":"2020","unstructured":"Delgado A, Cordero GGE, Marcos S, Cordero-Ampuero J (2020) Influence of cognitive impairment on mortality, complications and functional outcome after hip fracture: dementia as a risk factor for sepsis and urinary infection. Injury 51(Suppl 1):S19\u2013s24","journal-title":"Injury"},{"issue":"3","key":"7540_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00774-018-0948-6","volume":"37","author":"I Kanazawa","year":"2019","unstructured":"Kanazawa I, Takeno A, Tanaka KI, Yamane Y, Sugimoto T (2019) Osteoporosis and vertebral fracture are associated with deterioration of activities of daily living and quality of life in patients with type 2 diabetes mellitus. J Bone Miner Metab 37(3):503\u2013511","journal-title":"J Bone Miner Metab"},{"issue":"7","key":"7540_CR21","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00198-019-04922-x","volume":"30","author":"P Benzinger","year":"2019","unstructured":"Benzinger P, Riem S, Bauer J, Jaensch A, Becker C, B\u00fcchele G et al (2019) Risk of institutionalization following fragility fractures in older people. Osteoporos Int 30(7):1363\u20131370","journal-title":"Osteoporos Int"},{"issue":"1","key":"7540_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","volume":"15","author":"F Borgstr\u00f6m","year":"2020","unstructured":"Borgstr\u00f6m F, Karlsson L, Orts\u00e4ter G, Norton N, Halbout P, Cooper C et al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15(1):59","journal-title":"Arch Osteoporos"},{"issue":"3","key":"7540_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00198-023-07012-1","volume":"35","author":"L Vandenput","year":"2024","unstructured":"Vandenput L, Johansson H, McCloskey EV, Liu E, Schini M, \u00c5kesson KE et al (2024) A meta-analysis of previous falls and subsequent fracture risk in cohort studies. Osteoporos Int 35(3):469\u2013494","journal-title":"Osteoporos Int"},{"issue":"10","key":"7540_CR24","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00198-008-0588-0","volume":"19","author":"ND Nguyen","year":"2008","unstructured":"Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19(10):1431\u20131444","journal-title":"Osteoporos Int"},{"issue":"1","key":"7540_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40520-024-02826-3","volume":"36","author":"N Veronese","year":"2024","unstructured":"Veronese N, Briot K, Gua\u00f1abens N, Albergaria BH, Alokail M, Al-Daghri N et al (2024) Recommendations for the optimal use of bone forming agents in osteoporosis. Aging Clin Exp Res 36(1):167","journal-title":"Aging Clin Exp Res"},{"issue":"7","key":"7540_CR26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K et al (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33(7):1219\u20131226","journal-title":"J Bone Miner Res"},{"issue":"6","key":"7540_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/00325481.2022.2069582","volume":"134","author":"MR McClung","year":"2022","unstructured":"McClung MR, Rothman MS, Lewiecki EM, Hanley DA, Harris ST, Miller PD et al (2022) The role of osteoanabolic agents in the management of patients with osteoporosis. Postgrad Med 134(6):541\u2013551","journal-title":"Postgrad Med"},{"issue":"3","key":"7540_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s41999-021-00471-x","volume":"12","author":"F Lombardi","year":"2021","unstructured":"Lombardi F, Paoletti L, Carrieri B, Dell\u2019Aquila G, Fedecostante M, Di Muzio M et al (2021) Underprescription of medications in older adults: causes, consequences and solutions-a narrative review. Eur Geriatr Med 12(3):453\u2013462","journal-title":"Eur Geriatr Med"},{"issue":"4","key":"7540_CR29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40520-022-02100-4","volume":"34","author":"EM Curtis","year":"2022","unstructured":"Curtis EM, Reginster JY, Al-Daghri N, Biver E, Brandi ML, Cavalier E et al (2022) Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res 34(4):695\u2013714","journal-title":"Aging Clin Exp Res"},{"issue":"11","key":"7540_CR30","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1185\/03007990802466595","volume":"24","author":"H Minne","year":"2008","unstructured":"Minne H, Audran M, Sim\u00f5es ME, Obermayer-Pietsch B, Sigur\u00f0sson G, Mar\u00edn F et al (2008) Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin 24(11):3117\u20133128","journal-title":"Curr Med Res Opin"},{"key":"7540_CR31","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2147\/CIA.S120175","volume":"11","author":"A Nishikawa","year":"2016","unstructured":"Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H (2016) Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clin Interv Aging 11:1653\u20131659","journal-title":"Clin Interv Aging"},{"key":"7540_CR32","unstructured":"Eli Lilly Nederland B.V (2021) Forsteo 20 micrograms\/80 microliters solution for injection in pre-filled pen. Summary of product characteristics. [cited 2025 May 22].Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/forsteo-epar-product-information_en.pdf"},{"key":"7540_CR33","unstructured":"International Agency for Research on Cancer, World Health Organization (2022) Cancer today-estimated number of prevalent cases (1-year). Available from:\u00a0https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/pieprevalencemode=cancer&types=2&group_populations=1&show_table_pie=1&sexes=1&cancers=39&age_start=16&populations=100_112_191_196_203_208_233_246_250_276_300_348_352_372_380_40_428_440_442_470_498_499_528_56_578_616_620_642_64_3_688_70_703_705_724_752_756_8_804_807_826 . Accessed 6 Dec 2024"},{"key":"7540_CR34","unstructured":"UCB Pharma S.A (2024) Evenity 105 mg solution for injection in pre-filled pen and pre-filled syringe. Summary of product characteristics. [cited 2025 May 22]. Availablefrom: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evenity-epar-product-information_en.pdf"},{"key":"7540_CR35","unstructured":"Administration USFD (2019) FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-osteoporosis-postmenopausal-women-high-risk-fracture. Accessed 2025-04-05"},{"issue":"8","key":"7540_CR36","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","volume":"37","author":"PD Miller","year":"2022","unstructured":"Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E et al (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37(8):1437\u20131445","journal-title":"J Bone Miner Res"},{"issue":"4","key":"7540_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jocd.2013.09.018","volume":"17","author":"EM Lewiecki","year":"2014","unstructured":"Lewiecki EM, Miller PD, Harris ST, Bauer DC, Davison KS, Dian L et al (2014) Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. J Clin Densitom 17(4):490\u2013495","journal-title":"J Clin Densitom"},{"key":"7540_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.arr.2014.02.003","volume":"14","author":"D Bolignano","year":"2014","unstructured":"Bolignano D, Mattace-Raso F, Sijbrands EJ, Zoccali C (2014) The aging kidney revisited: a systematic review. Ageing Res Rev 14:65\u201380","journal-title":"Ageing Res Rev"},{"issue":"2","key":"7540_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","volume":"30","author":"F Festuccia","year":"2017","unstructured":"Festuccia F, Jafari MT, Moioli A, Fofi C, Barberi S, Amendola S et al (2017) Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol 30(2):271\u2013279","journal-title":"J Nephrol"},{"issue":"1","key":"7540_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bone.2010.12.024","volume":"49","author":"PD Miller","year":"2011","unstructured":"Miller PD (2011) The kidney and bisphosphonates. Bone 49(1):77\u201381","journal-title":"Bone"},{"issue":"4","key":"7540_CR41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.kint.2024.06.024","volume":"106","author":"JM Herold","year":"2024","unstructured":"Herold JM, Wiegrebe S, Nano J, Jung B, Gorski M, Thorand B et al (2024) Population-based reference values for kidney function and kidney function decline in 25- to 95-year-old Germans without and with diabetes. Kidney Int 106(4):699\u2013711","journal-title":"Kidney Int"},{"key":"7540_CR42","unstructured":"Roche Registration GmbH (2021) Bondronat 2 mg\/ml Konzentrat zur Herstellung einer Infusionsl\u00f6sung. Summary of product characteristics. [cited 2025 May 22]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bondronat-epar-product-information_en.pdf"},{"issue":"1","key":"7540_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3\u201323","journal-title":"J Bone Miner Res"},{"issue":"3","key":"7540_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40618-023-02219-9","volume":"47","author":"M Schini","year":"2024","unstructured":"Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey EV (2024) An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest 47(3):501\u2013511","journal-title":"J Endocrinol Invest"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07540-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07540-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07540-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T20:27:26Z","timestamp":1751315246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07540-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7540"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07540-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TT is a member in the data commission of GiB-DAT. RS and MD are members of the osteoporosis guideline commission. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}